How the pandemic has changed our approach to stakeholder engagement

McKinsey & Company recently undertook a survey of senior executives in commercial roles within global pharma, to understand their thoughts on how the pandemic has influenced and changed the strategic and operational approach to ongoing engagement.

The report focuses on the acceleration of certain commercial-organizational trends, with building digital capabilities taking precedence. The priority was to recreate engagement virtually and without placing an additional burden on already stretched stakeholders.

There was an overwhelming view that companies would embrace agile ways of working, with raising digital capabilities, expanding field roles, increasing subject matter expert accessibility for customers, proactive marketing and new business development capabilities, seen as having high value.

In summary, the report highlights the opportunity the pandemic has presented to revisit investment in time and resources. It illustrates the importance of delivering relevant communications to HCPs, particularly given the additional pressures they are facing. Quality over quantity definitely wins.

To read the full report, visit https://www.mckinsey.com/industries/life-sciences/our-insights/a-new-operating-model-for-pharma-how-the-pandemic-has-influenced-priorities

Related news


Seeing the Value of Scientific Content

In Pharmaceutical Commerce magazine, Tangent90 CEO Jan van den Burg discusses the value that HCPs place on scientific content and highlights the opportunity that pharma should be taking now.


Need to scale up fast? Ready-made content can help

Veeva recently published an eBook which discusses the best practice approach for supporting emerging pharma to launch and scale content faster. It focuses on how digital communications have allowed field teams to spend more quality time with HCPs. What can pharma’s brand teams do to support the increase needed?

Using next best action to inform your engagement strategy

We have been inundated with discussions about big data. Information that can help inform decision making is an output of nearly every phase in life sciences. The industry, with the increased use of digital channels, has been able to collect more data but is this being used to optimise their HCP engagement strategies?

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.